RENX to present at 39th JP Morgan Healthcare Conf.

RNS Number : 3438K

Renalytix AI PLC

04 January 2021

 

Renalytix AI plc

("RenalytixAI" or the "Company")

RenalytixAI to Present at the 39^th Annual J.P. Morgan Healthcare Conference

NEW YORK, 4 January 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the Company will be presenting at the upcoming 39^th Annual J.P. Morgan Virtual Healthcare Conference.

RenalytixAI's management is scheduled to present on Wednesday, January 13 at 10:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at investors.renalytixai.com .

For further information, please contact:

Renalytix AI plc		www.renalytixai.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker )		Tel: [phone]
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)		Tel: [phone]
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: [phone] or  [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com .

Disclosure Information

Renalytix AI plc uses filings with the Securities and Exchange Commission, its website ( www.renalytixai.com ), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

 

END

 

 

NRABXGDBGXGDGBB